An early warning test for Alzheimer’s disease could enable doctors to deliver treatment 10 years before a diagnosis is usually made, helping to delay the onset of symptoms.

If you are like a lot of people, you might be anxious about the risk of getting dementia as you age. The lifetime risk of ...

Proposed Operation Warp Speed for Alzheimer’s: an acceleration fund to fast-track cures and slash trillion-dollar costs.

The involvement of glial cells in Alzheimer's disease (AD) has been mostly viewed as a secondary adaptive response to ...

A look at the clinical progress of anti-Aβ monoclonal antibodies and how precision delivery is shaping the next generation of ...

Panelists discuss how identifying candidates for anti-amyloid therapy requires precise evaluation of disease stage, cognitive ...

Following the hard-won success of early anti-amyloid drugs, a new generation of Alzheimer’s modalities—from tau-targeting ...

Three years after the accelerated approval of its anti-amyloid Alzheimer’s therapy, Biogen—neck and neck in the market with ...

Novartis has agreed to pay up to $1.7 billion to license an experimental Alzheimer’s therapy from China-based SciNeuro, a ...

Under the deal, SciNeuro will receive $165m upfront and could earn up to $1.5bn in milestones.

SciNeuro Pharmaceuticals today announced it has entered into a worldwide licensing and collaboration agreement with Novartis Pharma AG, to advance SciNeuro's novel amyloid beta targeted antibody ...

Two variants in a single gene are implicated in almost all Alzheimer’s and nearly half of all dementia cases, according to ...